Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
3.07 | 0.04 (1.15%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 2,974 |
| Date : | 12-12-2025 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field [...]
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by [...]
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partnerships, Innovation, and Value-Driven Expansion Company Reaffirms Commitment to Rewarding Shareholders, Including [...]
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two [...]
Investors Tools